BONE-INDUCTIVE EFFICACY OF RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 EXPRESSED IN ESCHERICHIA COLI: AN EXPERIMENTAL STUDY IN RAT MANDIBULAR DEFECTS

• Published in: Scandinavian journal of plastic and reconstructive surgery and hand surgery Vol. 34; no. 4; pp. 289 - 299
• Main Author: Morihiro Kimura, Ming Zhao, Göran Zellin, Anders Linde
• Format: Journal Article
• Language: English
• Published: Basingstoke Informa UK Ltd 2000; Taylor & Francis
• Subjects: Animals; Biological and medical sciences; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins - administration & dosage; Bone Morphogenetic Proteins - biosynthesis; Bone Morphogenetic Proteins - genetics; Bone Morphogenetic Proteins - pharmacology; Bone Regeneration Osteoinduction Osteogenesis Bone Morphogenetic Protein Recombinant Expression Escherichia Coli Artificial Membrane E-PTFE; Disease Models, Animal; Ent. Stomatology; Escherichia coli - genetics; Escherichia coli - metabolism; Facial bones, jaws, teeth, parodontium: diseases, semeiology; Genetic Vectors; Humans; Male; Mandibular Injuries - diet therapy; Mandibular Injuries - drug therapy; Medical sciences; Non tumoral diseases; Osteogenesis - drug effects; Otorhinolaryngology. Stomatology; Pharmacology. Drug treatments; Rats; Rats, Sprague-Dawley; Recombinant Proteins - pharmacology; Transforming Growth Factor beta; Mandible; Rat; Stomatology; Induction; Escherichia coli; Rodentia; Diseases of the osteoarticular system; Experimental study; Regeneration; Vertebrata; Chemotherapy; Mammalia; Bone morphogenetic protein; Treatment; Animal; Bacteria; Biological effect; Lesion; Osteogenesis; Enterobacteriaceae; Maxillary disease
• ISSN: 0284-4311; 1651-2073
• DOI: 10.1080/028443100750059057

Because to our knowledge the efficacy of prokaryotically expressed recombinant human bone morphogenetic proteins (rhBMP) to promote orthotopic osteogenesis has not previously been investigated, our aim was to test the efficacy of rhBMP-2 produced in Escherichia coli to promote bone healing in a standardised experimental bone healing model in rat mandibles. Different doses of rhBMP-2 were delivered in an absorbable collagen sponge carrier, and microporous barrier membranes were placed over half the number of defects in each treatment group, thereby making intraosseous cells the only recruitment source for new osteogenic cells. Results were evaluated by computerised image analysis after 12 and 24 days. The relative efficacy of rhBMP-2 preparations of different purity was also compared. E coli-produced rhBMP-2 stimulated bone healing, but its efficacy was estimated to be about one order of magnitude less than that of rhBMP-2 expressed in eukaryotic cells. We conclude that bacterially expressed rhBMP-2 is osteogenic in vivo, although higher doses will be required than of rhBMP-2 expressed in mammalian cell lines.